FIGURE 6 from Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner

Primary tumor cells express CD32. A, Expression levels of FCGR2A across TCGA tumors were assessed by GEPIA. TCGA study abbreviations: LAML, acute myeloid leukemia; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD, colon adenocarcinoma; KIRP, kidney renal papillary carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; STAD, stomach adenocarcinoma; UCS, uterine carcinosarcoma. B, Lung tumor tissue arrays were subjected to IHC to detect CD32 expression in LUAD and LUSC (×400). C, LAML cells were stained with anti-CD32 or isotype control Abs and analyzed by flow cytometry. D, iNKT cells sorted using Vα24-FITC Ab/FITC MicroBeads were maintained in the presence of IL2 overnight, washed twice, and then cultured in fresh medium with IL2 for 4 or 5 days. iNKT cells treated with the 6B11 mAb (50 ng/mL) overnight were washed and cocultured with LAML or K562 cells (control) at an E/T ratio of 2:1. A CD107a assay was then performed. PT, patient.